A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
- A. M. Evens
- , K. R. Carson
- , J. Kolesar
- , C. Nabhan
- , I. Helenowski
- , N. Islam
- , B. Jovanovic
- , P. M. Barr
- , P. F. Caimi
- , S. A. Gregory
- , L. I. Gordon
Research output: Contribution to journal › Article › peer-review
55
Scopus
citations